{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:25:28Z","timestamp":1793395528849,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.pupt.2023.102266","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T11:56:07Z","timestamp":1699876567000},"page":"102266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Tyvaso DPI: Drug-device characteristics and patient clinical considerations"],"prefix":"10.1016","volume":"83","author":[{"given":"Colleen","family":"McEvoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Argula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Eagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Smutney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany N.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Broderick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pupt.2023.102266_bib1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"25","key":"10.1016\/j.pupt.2023.102266_bib2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMra2000348","article-title":"Pulmonary arterial hypertension","volume":"385","author":"Hassoun","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.pupt.2023.102266_bib3","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/jama.2022.4402","article-title":"Diagnosis and treatment of pulmonary arterial hypertension: a review","volume":"327","author":"Ruopp","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.pupt.2023.102266_bib4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/MCP.0000000000000790","article-title":"Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment","volume":"27","author":"Behr","year":"2021","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"25","key":"10.1016\/j.pupt.2023.102266_bib5","doi-asserted-by":"crossref","first-page":"D109","DOI":"10.1016\/j.jacc.2013.10.036","article-title":"Pulmonary hypertension in chronic lung diseases","volume":"62","author":"Seeger","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.pupt.2023.102266_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American thoracic society\/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.pupt.2023.102266_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur. Respir. J."},{"issue":"38","key":"10.1016\/j.pupt.2023.102266_bib8","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.pupt.2023.102266_bib9","first-page":"391","article-title":"Prostacyclin therapy for pulmonary arterial hypertension","volume":"37","author":"Ruan","year":"2010","journal-title":"Tex. Heart Inst. J."},{"key":"10.1016\/j.pupt.2023.102266_bib10","series-title":"[Prescribing Information]","year":"2022"},{"key":"10.1016\/j.pupt.2023.102266_bib11","series-title":"TYVASO (Treprostinil) [Prescribing Information]","year":"2023"},{"key":"10.1016\/j.pupt.2023.102266_bib12","series-title":"Letairis [package Insert]","year":"2019"},{"issue":"1","key":"10.1016\/j.pupt.2023.102266_bib13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2213-2600(20)30356-8","article-title":"Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.pupt.2023.102266_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1164\/rccm.201403-0446OC","article-title":"Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia","volume":"190","author":"Corte","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"18","key":"10.1016\/j.pupt.2023.102266_bib15","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa1811737","article-title":"Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis","volume":"379","author":"Kolb","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.pupt.2023.102266_bib16","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.pupt.2023.102266_bib17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"5","key":"10.1016\/j.pupt.2023.102266_bib18","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1183\/13993003.01537-2014","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.pupt.2023.102266_bib19","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis","volume":"363","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2023.102266_bib20","series-title":"Treprostinil Inhalation Powder Investigator's Brochure","year":"2020"},{"issue":"2","key":"10.1016\/j.pupt.2023.102266_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12063","article-title":"BREEZE: open\u2010label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI\u2122 in patients with pulmonary arterial hypertension","volume":"12","author":"Spikes","year":"2022","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.pupt.2023.102266_bib22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.addr.2014.04.004","article-title":"Technological and practical challenges of dry powder inhalers and formulations","volume":"75","author":"Hoppentocht","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.pupt.2023.102266_bib23","first-page":"367","article-title":"The inhalation of drugs: advantages and problems","volume":"50","author":"Rau","year":"2005","journal-title":"Respir. Care"},{"issue":"1","key":"10.1016\/j.pupt.2023.102266_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","article-title":"Inhaled medicines: past, present, and future","volume":"74","author":"Anderson","year":"2022","journal-title":"Pharmacol. Rev."},{"issue":"12","key":"10.1016\/j.pupt.2023.102266_bib25","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.healun.2011.08.019","article-title":"Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension","volume":"30","author":"Benza","year":"2011","journal-title":"J. Heart Lung Transplant."},{"issue":"18","key":"10.1016\/j.pupt.2023.102266_bib26","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.pupt.2023.102266_bib27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.pupt.2023.102266_bib28","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s40262-016-0409-0","article-title":"A comprehensive review of treprostinil pharmacokinetics via four routes of administration","volume":"55","author":"Kumar","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.pupt.2023.102266_bib29","series-title":"Goodman and Gilman's the Pharmacological Basis of Therapeutics","first-page":"601","article-title":"Lipid-derived autacoids: eicosanoids and platelet-activating factor","author":"Campbell","year":"1996"},{"issue":"9","key":"10.1016\/j.pupt.2023.102266_bib30","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1007\/s12325-022-02229-8","article-title":"The antifibrotic effects of inhaled treprostinil: an emerging option for ILD","volume":"39","author":"Kolb","year":"2022","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.pupt.2023.102266_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/193229680900300320","article-title":"Technosphere insulin: defining the role of Technosphere particles at the cellular level","volume":"3","author":"Angelo","year":"2009","journal-title":"J. Diabetes Sci. Technol."},{"issue":"6","key":"10.1016\/j.pupt.2023.102266_bib32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/1932296814555820","article-title":"Afrezza inhaled insulin","volume":"8","author":"Klonoff","year":"2014","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.pupt.2023.102266_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121457","article-title":"The future of dry powder inhaled therapy: promising or discouraging for systemic disorders?","volume":"614","author":"Ye","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.pupt.2023.102266_bib34","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/jps.2600820412","article-title":"Epithelial transport of drugs in cell culture. VIII: effects of sodium dodecyl sulfate on cell membrane and tight junction permeability in human intestinal epithelial (Caco-2) cells","volume":"82","author":"Anderberg","year":"1993","journal-title":"J. Pharmaceut. Sci."},{"issue":"6","key":"10.1016\/j.pupt.2023.102266_bib35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1023\/A:1018909210879","article-title":"Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route","volume":"10","author":"Anderberg","year":"1993","journal-title":"Pharm. Res. (N. Y.)"},{"issue":"9","key":"10.1016\/j.pupt.2023.102266_bib36","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/jps.2600810908","article-title":"Epithelial transport of drugs in cell culture. VII: effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells","volume":"81","author":"Anderberg","year":"1992","journal-title":"J. Pharmaceut. Sci."},{"issue":"5","key":"10.1016\/j.pupt.2023.102266_bib37","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1177\/193229681000400515","article-title":"Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine","volume":"4","author":"Potocka","year":"2010","journal-title":"J. Diabetes Sci. Technol."},{"issue":"12","key":"10.1016\/j.pupt.2023.102266_bib38","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.2337\/dc15-0629","article-title":"Inhaled Technosphere insulin versus inhaled Technosphere placebo in insulin-na\u00efve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pupt.2023.102266_bib39","series-title":"Tyvaso DPI: Instructions for Use","year":"2022"},{"issue":"4","key":"10.1016\/j.pupt.2023.102266_bib40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/17425247.2016.1224846","article-title":"Dry powder inhalation: past, present and future","volume":"14","author":"De Boer","year":"2017","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.pupt.2023.102266_bib41","series-title":"Fundamentals of Dry Powder Inhaler Technology","first-page":"213","author":"Hickey","year":"2018"},{"issue":"4","key":"10.1016\/j.pupt.2023.102266_bib42","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1513\/pats.200409-046TA","article-title":"Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery","volume":"1","author":"Heyder","year":"2004","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"8","key":"10.1016\/j.pupt.2023.102266_bib43","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.rmed.2014.05.009","article-title":"The clinical relevance of dry powder inhaler performance for drug delivery","volume":"108","author":"Demoly","year":"2014","journal-title":"Respir. Med."},{"issue":"12","key":"10.1016\/j.pupt.2023.102266_bib44","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1164\/rccm.200410-1414OC","article-title":"Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size","volume":"172","author":"Usmani","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102266_bib45","series-title":"Technosphere\/insulin: Mimicking Endogenous Insulin Release. Modified Release Drug Delivery Technology","author":"Leone-Bay","year":"2008"},{"key":"10.1016\/j.pupt.2023.102266_bib46","unstructured":"United Therapeutics C. Data on File."},{"key":"10.1016\/j.pupt.2023.102266_bib47","series-title":"Pulmonary Drug Delivery - Simplified","first-page":"18","author":"Leone-Bay","year":"2011"},{"issue":"1","key":"10.1016\/j.pupt.2023.102266_bib48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/fps.90","article-title":"Technosphere: new drug delivery system for inhaled insulin","volume":"13","author":"Sarala","year":"2012","journal-title":"Future Prescr."},{"issue":"9","key":"10.1016\/j.pupt.2023.102266_bib49","first-page":"1209","article-title":"Dry powder inhaler formulation","volume":"50","author":"Telko","year":"2005","journal-title":"Respir. Care"},{"issue":"18","key":"10.1016\/j.pupt.2023.102266_bib50","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1111\/bph.15197","article-title":"Cough as an adverse effect on inhalation pharmaceutical products","volume":"177","author":"Chang","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pupt.2023.102266_bib51","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020985345","article-title":"Impact of human behavior on inspiratory flow profiles in patients with pulmonary arterial hypertension using AOS dry powder inhaler device","volume":"11","author":"Sahay","year":"2021","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.pupt.2023.102266_bib52","author":"U.S. Food and Drug Administration"},{"issue":"1","key":"10.1016\/j.pupt.2023.102266_bib53","doi-asserted-by":"crossref","DOI":"10.1186\/s40248-015-0012-5","article-title":"Dry powder inhalers and the right things to remember: a concept review","volume":"10","author":"Dal Negro","year":"2015","journal-title":"Multidiscip. Respir. Med."},{"key":"10.1016\/j.pupt.2023.102266_bib54","first-page":"257","article-title":"Malmberg. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters","year":"2010","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.pupt.2023.102266_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jamp.2019.1556","article-title":"The confusing world of dry powder inhalers: it is all about inspiratory pressures, not inspiratory flow rates","volume":"33","author":"Clark","year":"2020","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.pupt.2023.102266_bib56","series-title":"Innovation IN Drug Delivery by Inhalation","first-page":"4","author":"Leone-Bay","year":"2010"},{"issue":"4","key":"10.1016\/j.pupt.2023.102266_bib57","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2006.10.010","article-title":"Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study","volume":"6","author":"Westerman","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2023.102266_bib58","series-title":"MannKind Inhalation Technology Overview","year":"2021"},{"key":"10.1016\/j.pupt.2023.102266_bib59","series-title":"TreT Performance at Varied Flow Rates in ACA","author":"Copropration","year":"2021"},{"key":"10.1016\/j.pupt.2023.102266_bib60","series-title":"MannKind Copropration. Tre-T Performance at Varied Flow Rates [Device Technical Report]","year":"2020"},{"issue":"1","key":"10.1016\/j.pupt.2023.102266_bib61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1183\/09031936.04.00095804","article-title":"Respiratory muscle dysfunction in idiopathic pulmonary arterial hypertension","volume":"25","author":"Meyer","year":"2005","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.pupt.2023.102266_bib62","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/jcm9020410","article-title":"Skeletal and respiratory muscle dysfunctions in pulmonary arterial hypertension","volume":"9","author":"Riou","year":"2020","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.pupt.2023.102266_bib63","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1152\/japplphysiol.01010.2002","article-title":"Accuracy of noninvasive estimates of respiratory muscle effort during spontaneous breathing in restrictive diseases","volume":"95","author":"Garcia-Rio","year":"2003","journal-title":"J. Appl. Physiol."},{"issue":"1","key":"10.1016\/j.pupt.2023.102266_bib64","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1183\/09031936.00109512","article-title":"Respiratory muscle function in interstitial lung disease","volume":"42","author":"Walterspacher","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.pupt.2023.102266_bib65","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.202107-1625ED","article-title":"Upfront combination therapy for pulmonary arterial hypertension: time to Be more ambitious than AMBITION","volume":"204","author":"Cascino","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10","key":"10.1016\/j.pupt.2023.102266_bib66","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/S2213-2600(22)00304-6","article-title":"Phenotypes of idiopathic pulmonary arterial hypertension","volume":"10","author":"El-Kersh","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.pupt.2023.102266_bib67","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/jcpt.12170","article-title":"Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series","volume":"39","author":"Enderby","year":"2014","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.pupt.2023.102266_bib68","article-title":"Hemodynamics of treprostinil inhalation solution and treprostinil inhalation powder","author":"El-Kersh","year":"2022","journal-title":"Am. J. Therapeut."},{"issue":"5","key":"10.1016\/j.pupt.2023.102266_bib69","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/87551225211031331","article-title":"A systematic review on KAP of nebulization therapy at home","volume":"37","author":"Sivadasan","year":"2021","journal-title":"J. Pharm. Technol."},{"issue":"3","key":"10.1016\/j.pupt.2023.102266_bib70","doi-asserted-by":"crossref","first-page":"P7","DOI":"10.1164\/rccm.2023C7","article-title":"Nebulizer breathing treatments at home","volume":"202","author":"Sockrider","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2023.102266_bib71","series-title":"Dose-response Analyses of Treprostinil Inhalation Powder in PAH and its Effect on 6MWD. Presented at: American Thoracic Society","author":"Ramani","year":"2023"},{"key":"10.1016\/j.pupt.2023.102266_bib72","series-title":"BREEZE: Clinical Outcomes and Pharmacokinetics of Treprostinil Inhalation Powder (Tyvaso DPI). Presented at","author":"Shapiro","year":"2021"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553923000780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:33:04Z","timestamp":1761082384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553923000780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":72,"alternative-id":["S1094553923000780"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102266","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyvaso DPI: Drug-device characteristics and patient clinical considerations","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2023.102266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102266"}}